Literature DB >> 6327488

Delta agent infection in patients with chronic liver diseases and hepatocellular carcinoma--an infrequent finding in Taiwan.

D S Chen, M Y Lai, J L Sung.   

Abstract

Taiwanese have a high prevalence of HBsAg carrier rate and chronic liver diseases. To evaluate the role of delta (delta) agent infection in our patients, 45 HBsAg-positive patients with chronic active hepatitis, 4 with chronic persistent hepatitis and 11 with HBsAg-positive hepatocellular carcinoma were studied for delta antibody by radioimmunoassay of serum; liver was studied for delta antigen by immunofluorescence in 23 patients. delta Antibody was only found in three patients with chronic active hepatitis (6.7%); the prevalence was 5% in HBsAg-positive chronic liver diseases and hepatocellular carcinoma. None of the liver specimens studied had delta antigen. The study indicates that delta agent infection does not seem to play an important role in chronic liver diseases and hepatocarcinoma in Chinese who live in Taiwan, despite a high prevalence of chronic hepatitis B virus infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327488     DOI: 10.1002/hep.1840040324

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

1.  Profile of Ding-Shinn Chen.

Authors:  Philip Downey
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

2.  Anti-delta antibody in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia.

Authors:  S J Ashraf; S C Arya; C M Parande; R Sahay; A R Ageel
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

3.  [Preliminary study of delta-agent in liver tissue of patients with virus hepatitis B].

Authors:  L J Hao; Y Y Zhang
Journal:  Acta Acad Med Wuhan       Date:  1985

4.  New enzyme-linked immunosorbent assay for detection of antibodies against hepatitis delta virus using a hepatitis delta antigen derived from a Taiwanese clone and comparison to the Abbott radioimmunoassay.

Authors:  Yung-Bin Kuo; Mei Chao; Yi-Hsuan Lee; Chau-Ting Yeh; Err-Cheng Chan
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

5.  Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan.

Authors:  Sui-Yuan Chang; Chia-Ling Yang; Wei-Shin Ko; Wen-Chun Liu; Chi-Ying Lin; Cheng-Hsin Wu; Yi-Chin Su; Shu-Fang Chang; Mao-Yuan Chen; Wang-Huei Sheng; Chien-Ching Hung; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

6.  Serological markers of hepatitis B virus and hepatitis D virus infections in Greek adults with primary hepatocellular carcinoma.

Authors:  N C Tassopoulos; G Theodoropoulos; M H Sjogren; R Engle; R H Purcell
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

Review 7.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

8.  Hepatitis D virus genotypes in intravenous drug users in taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes.

Authors:  Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 9.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 10.  Delta and non-A, non-B hepatitis viruses.

Authors:  F Bonino; M Baldi; A Demartini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.